Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Zhang



Author of

  • +

    P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.11-036 - The efficacy and safety of sunitinib in EGFR-TKI pretreated advanced non-small cell lung cancer: a retrospective review from Chinese patients at a single institution (ID 2534)

      09:30 - 09:30  |  Author(s): J. Zhang

      • Abstract

      Background
      Sunitinib is an oral, selective multi-targeted tyrosine kinase inhibitor (TKI) with antiangiogenic and antitumor activities. The result from a previous study suggested that the treatment of sunitinib might present favorable survival outcomes for the EGFR-TKI pretreated NSCLC Chinese patients. This study was therefore to evaluate the efficacy and toxicity of this therapeutic strategy.

      Methods
      This is a retrospective review of 30 stage IV NSCLC patients who received sunitinib as salvage therapy in Shanghai Chest hospital, from January 2009 until August 2011. All of the patients had previously been treated with EGFR-TKIs. Kaplan-Meier method was employed to estimate the median progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox proportional hazard regression analyses were carried out to determine the important prognostic risk factors influencing NSCLC survival.

      Results
      The median PFS of all 30 treated patients was 1.25 months (95% CI: 0.90-1.9 months), and the median OS was 3.40 months (95% CI: 3.00-6.80 months). Of the 29 patients eligible for efficacy evaluation, none achieved partial response. Cox regression analysis suggested that Eastern Cooperative Oncology Group (ECOG) performance status (PS) is predictive of both PFS (p=0.001) and OS (p<0.001). Hand-foot syndrome (53.3%), mucositis (40.0%), rash (36.7%) and diarrhea (33.3%) were most commonly reported adverse events.

      Conclusion
      In this study, the sunitinib treatment did not demonstrate overall clinical benefits to the EGFR-TKI pretreated NSCLC Chinese patients. Most side effects were mild to moderate. These results need further validation in prospective studies.